HC Wainwright Has Bullish Forecast for DNLI FY2028 Earnings
HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...
Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird
Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on ...
JOST Werke (ETR:JST) Stock Price Down 0.5% – Here’s What Happened
JOST Werke SE (ETR:JST – Get Free Report) shares were down 0.5% during mid-day trading on Thursday . The company traded as low as €46.35 ($47.78) and last traded at €46.45 ($47.89). Approximately ...
ReGen III (CVE:GIII) Trading 1.2% Higher – Should You Buy?
Shares of ReGen III Corp. (CVE:GIII – Get Free Report) rose 1.2% during trading on Thursday . The company traded as high as C$0.43 and last traded at C$0.43. Approximately 56,510 shares traded hands ...
ECR Minerals (LON:ECR) Shares Down 0.3% – Time to Sell?
Shares of ECR Minerals plc (LON:ECR – Get Free Report) were down 0.3% on Thursday . The stock traded as low as GBX 0.28 ($0.00) and last traded at GBX 0.29 ($0.00). Approximately 43,026,016 shares ...
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Denali Therapeutics announces U.S. FDA BTD granted for tividenofusp
Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
Denali Therapeutics (NASDAQ:DNLI) Given New $87.00 Price Target at HC Wainwright
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...
Cal-Maine Foods (NASDAQ:CALM) Downgraded to “Hold” Rating by StockNews.com
StockNews.com lowered shares of Cal-Maine Foods (NASDAQ:CALM – Free Report) from a buy rating to a hold rating in a research note published on Tuesday morning. Separately, Stephens began coverage on ...